SAN Sanofi

By Anthony O. Goriainoff

AstraZeneca PLC said Friday that nirsevimab, a treatment for the prevention of respiratory syncytial virus, a lower-respiratory-tract disease in infants, has been approved in the European Union.

The Anglo-Swedish pharma major said approval for the treatment, know commercially as Beyfortus, was based on results from the Beyfortus clinical development program. This approval follows from September's recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, the company said.

London-listed AstraZeneca said the European Commission was the first regulatory body to grant Beyfortus an approval.

Beyfortus is being developed jointly by AstraZeneca and Sanofi and is an investigational long-acting antibody designed for all infants for protection against RSV disease from birth.

RSV is a common and very contagious seasonal virus, infecting nearly all children by the age of two, the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

November 04, 2022 03:37 ET (07:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.